Verana Health

CASE STUDY | ARVO 2026

Large-scale Real-World Observational Study Replicates Primary Efficacy Endpoints of Landmark RCT Study into nAMD

Verana partnered with Regeneron on evaluating real-world visual acuity outcomes and treatment patterns for neovascular age-related macular degeneration (nAMD) by emulating the inclusion criteria of the benchmark VIEW 1 and VIEW 2 clinical trials. Findings presented the Association for Research in Vision and Ophthalmology (ARVO), 2022.

Background

- **Clinical Context:** Neovascular age-related macular degeneration (nAMD) is the leading cause of blindness in people over the age of 60.[1]
- **Initial Study:** VEGF Trap-Eye: Investigation of Efficacy and Safety in nAMD (VIEW 1, VIEW 2) Phase-3 studies led to FDA clearance of Regeneron's afilbercept for the treatment of nAMD in 2011.

Objective

Provide a proof-of-concept replicate of the VIEW 1 and VIEW 2 study design and evaluate the outcomes using real-world data.

1. Identify cohorts in IRIS Registry that emulate study arms of the VIEW studies
2. Using RWD, demonstrate the proportion of eyes maintaining vision was equivalent to the outcomes of the VIEW studies

Results

1. Verana Health was able to replicate all 3 arms from the VIEW studies
2. The primary outcome was equivalent to that of VIEW 1/2, indicating proof-of-concept

1,632
patients in enrolled in VIEW studies

7,669
patients identified in IRIS Registry

This study is the first time RWD has been used in an attempt to replicate primary outcomes of two large-scale clinical trials in ophthalmology.

Benchmarking real-world endpoints versus RCTs could be a valuable tool in validating the predictive ability of these endpoints as a measure of effectiveness.

1 Bressler NM. Jama. 2004;15:1900-1901. Verana Health Leads First-of-its-Kind Study Demonstrating Promise of Real-World Data in Ophthalmic Clinical Development Source: Gallivan MD, Garcia KM, Torres AZ, Lum F, Li C, Mbagwu M, Leng T. Emulating VIEW 1 and VIEW 2 Clinical Trial Outcome Data Using the American Academy of Ophthalmology IRIS® Registry. Presented at: Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; Denver, CO.